Please assess the completion status of the following clinical trial:

Trial Title: Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 18 to 30 kg/m2~* Females postmenopausal or surgically sterile~Exclusion Criteria:~* Any uncontrolled or active major systemic disease including, but not limited to: acromegaly (with or without pituitary surgery or radiation therapy), cardiac, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric, or neoplastic disorder with metastatic potential~* History or presence of malignancy within the past 5 years. Subjects who have been successfully treated (for 3 months or longer) with no recurrence of basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled.~* Use of any investigational drug within the past 60 days or 5 half-lives, whichever is longer~* Have a medically significant abnormality observed during screening or the admission physical examination or in any other baseline measurements~* Use of any prior medication without approval of the investigator within 14 days prior to admission~* Tested positive at screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab) or has a history of a positive result~* History of alcohol or substance abuse in the past 6 months~* Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this Phase 1 study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- CRN00808 Oral Solution (Type: EXPERIMENTAL): CRN00808 oral solution, single-dose
- CRN00808 Oral Capsule (Type: EXPERIMENTAL): CRN00808 oral capsule, single-dose and multiple-doses
- Placebo Oral Solution (Type: PLACEBO_COMPARATOR): Placebo oral solution, single-dose
- Placebo Oral Capsule (Type: PLACEBO_COMPARATOR): Placebo oral capsule, single-dose and multiple doses
- Midazolam Oral Solution (Type: OTHER): Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).